InvestWiser

Gubra A/S

GUBRANasdaq CopenhagenHealthcareMarket value 4.4 bn DKK
269.80DKK −6.6%
last day · Price as of 18 November 2026

The answer first

Does Gubra beat the market?

No, Gubra has not beaten the market over the last year.

Gubra−39.6%København (OMXCGI)+13.9%
  • The ranking · Quality, value and trend combined

    Better than 3% of Nordic stocks

    • Quality29
    • Value7
    • Trend13

    No. 184 of 195 in healthcare

Max for seven days

Follow Gubra with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Gubra

From today, at a price of 269.80 DKK. Write why you follow Gubra, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Gubra

Your first answer is free, no account needed.

Do you own Gubra, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Gubra and a few more. Free, no card.

Past year against the exchange and Super Stock
Gubra−39.6%København (OMXCGI)+13.9%Super Stock+44.6%
14 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Gubra has fallen 39.6% over the past year, including dividends.
  • Overall, Gubra ranks better than 3% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 58.1%. The price is 58.1% below its peak now.

Who owns Gubra? See the major shareholders and their stakes

What do analysts think of Gubra?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

3

Quality, value and trend together. Better than 3% of Nordic stocks.

No. 184 of 195 in healthcare

Quality29
The company · Fundamentals: the accounts

Low Weaker accounts than most: low profitability, high debt or uneven results.

No. 158 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.21
  • Asset turnoverSales divided by everything the company owns0.21
  • Return on equityProfit divided by equity−17.4%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value7
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 152 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity4.1
  • P/SPrice divided by sales15.7
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend13
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 150 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−31.1%
  • 6 months−20.6%
  • 9 months−28.4%
  • 12 months−39.6%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−11.5%
3 years, per year
+39.3%
5 years, per year
–
Year to date
−47.9%
Largest fall, 3 years
−58.1%
From a peak to the bottom
From the peak now
−58.1%
How far the price is from the peak
Volatility, 1 year
53.5%
How much the price swings over a year
Beta, 1 year
1.30
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Gubra

7 funds we follow own Gubra. The share is how much of the fund the stock makes up.

  • Norway1
  • Sweden2
  • Denmark4

From the funds' latest known holdings.

About Gubra

Gubra A/S is a company in healthcare, listed on Nasdaq Copenhagen. The share trades in DKK. It has around 330 employees.

Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry; and various services in vivo pharmacology, biomarker assays, bioinformatics, next gen sequencing, bioinformatics, and 2D and 3D histology with artificial intelligence pathology.

See the full analysis of Gubra.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Copenhagen

Explore the stock market